ARTICLE | Company News
Khepri other research news
August 1, 1994 7:00 AM UTC
The South San Francisco company received two Phase I SBIR grants to develop drugs for wound healing and neurologic diseases based on proteases and protease inhibitors.
A $67,000 grant from the NIH's Arthritis and Muscoskelatal and Skin Diseases division will fund the study of the protease inhibitory activity of agrin, a protein thought to be important in the formation and maintenance of the neuromuscular junction and in the regulation of protease activity associated with neurodegenerative diseases. ...